Given that there are currently no genetically-targeted therapies for HCC, inactivation of FGF19 without influencing liver metabolism or selective disruption of FGF19-FGFR4 interaction may be beneficial in treatment for metastatic HCC. This evidence concerns the gene FGF19 and hepatocellular carcinoma.